Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

Open access
Bahlis, Nizar J., Costello, Caitlin L., Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael H., Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M., Trudel, Suzanne, Jakubowiak, Andrzej, Gasparetto, Cristina, Chu, Michael P., Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M. · 2023 · Nature Medicine

Abstract

Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells. The MagnetisMM-1 trial evaluated its safety, pharmacokinetics and efficacy. Primary endpoints, including the incidence of dose-limiting toxicities as well as objective response rate (ORR) and duration of response (DOR), were met. Secondary efficacy endpoints included progression-free survival (PFS) and overall survival (OS). Eighty-eight patients with relapsed or refractory MM received elranatamab monotherapy, and 55 patients received elranatamab at efficacious doses. Patients had received a median of five prior regimens; 90.9% were triple-class refractory, 29.1% had high cytogenetic risk and 23.6% received prior BCMA-directed therapy. No dose-limiting toxicities were observed during dose escalation. Adverse events included cytopenias and cytokine release syndrome. Exposure was dose proportional. With a median follow-up of 12.0 months, the ORR was 63.6% and 38.2% of patients achieving complete response or better. For responders, the median DOR was 17.1 months. All 13 patients evaluable for minimal residual disease achieved negativity. Even after prior BCMA-directed therapy, 53.8% achieved response. For all 55 patients, median PFS was 11.8 months, and median OS was 21.2 months. Elranatamab achieved durable responses, manageable safety and promising survival for patients with MM. ClinicalTrials.gov Identifier: NCT03269136.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02589-w

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 160

Metadata

Authors
Bahlis, N. J., Costello, C. L., Raje, N. S., Levy, M. Y., Dholaria, B., Solh, M., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., Skoura, A., Chan, E. M., Trudel, S., Jakubowiak, A., Gasparetto, C., Chu, M. P., Dalovisio, A., Sebag, M., & Lesokhin, A. M.
Venue
Nature Medicine
Published
2023-10
Volume
29
Issue
10
Pages
2570-2576
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4387252273
Cited by
160
References
10
FWCI
28.33
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. https://app.cochat.ai/papers/10.1038/s41591-023-02589-w
The paper
Bahlis, N. J., Costello, C. L., Raje, N. S., Levy, M. Y., Dholaria, B., Solh, M., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., Skoura, A., Chan, E. M., Trudel, S., Jakubowiak, A., Gasparetto, C., Chu, M. P., Dalovisio, A., Sebag, M., & Lesokhin, A. M. (2023). Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02589-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.